| abstract |
The present invention relates to protracted humanninsulin derivatives in which the A21 and the B3 amino acidnresidues are, independently, any amino acid residue which cannbe coded for by the genetic code except Lys, Arg and Cys; Phe B1 nmay be deleted; the B30 amino acid residue isn a) a non-codable, lipophilic amino acid having fromn10 to 24 carbon atoms, in which case an acyl group of ancarboxylic acid with up to 5 carbon atoms is bound to the ∈-aminongroup of Lys 829 ; or b) the B30 amino acid residue is deleted or is anynamino acid residue which can be coded-for by the genetic codenexcept Lys, Arg and Cys, in any of which cases the ∈-aminongroup of Lys B29 has a lipophilic substituent; nand any Zn 2+ complexes thereof with the proviso that when B30 isnThr or Ala and A21 and B3 are both Asn, and Phe B1 is present,nthen the insulin derivative is always present as a Zn 2+ complex. |